DOP024 Tofacitinib achieves symptomatic improvement within 3 days in moderately to severely active ulcerative colitis, regardless of prior tumour necrosis factor inhibitor treatment status: results from OCTAVE induction 1 and 2
2018 ◽
Vol 12
(supplement_1)
◽
pp. S046-S048
◽
2004 ◽
Vol 63
(3)
◽
pp. 318-320
◽
2015 ◽
Vol 75
(4)
◽
pp. 785-786
◽
2012 ◽
Vol 72
(1)
◽
pp. 57-63
◽
2014 ◽
Vol 73
(11)
◽
pp. 2061-2062
◽
2019 ◽